Literature DB >> 27533979

NSAIDs are associated with increased risk of atrial fibrillation in patients with prior myocardial infarction: a nationwide study.

Anne-Marie Schjerning Olsen1, Emil L Fosbøl2, Jannik Pallisgaard3, Jesper Lindhardsen3, Morten Lock Hansen3, Lars Køber4, Peter R Hansen3, Christian Torp-Pedersen5, Gunnar H Gislason3.   

Abstract

AIMS: Non-steroidal anti-inflammatory drugs (NSAIDs) are associated with increased risk of cardiovascular disease. Yet, the risk of atrial fibrillation (AF) associated with NSAIDs among patients with prior myocardial infarction (MI) has not been examined, and such data could contribute considerably to the risk-benefit assessment of NSAID use in this clinical context. METHODS AND
RESULTS: Using nationwide administrative registries in Denmark, we studied patients aged ≥30 years admitted with first-time MI and without prior AF in the period of 1997-2011. Risk of AF associated with NSAID use vs. no NSAID use was analysed by multivariable time-dependent Cox proportional hazard models. Of the 86 496 patients [mean age 66 (SD 13) years; 64% men] included in this study, 44.1% filled at least one NSAID prescription after discharge from MI. During a mean follow-up of 5.3 years, 7831 (8.9%) developed AF. The confidence intervals rate (95% CI) of AF per 100 person-years with NSAID treatment was 2.2 (2.0-2.4) compared with 1.7 (1.6-1.7) without NSAIDs. In the adjusted model, the risk of AF after NSAID treatment increased [Hazard ratio (HR) 1.27 (1.14-1.40)]. An increased risk of AF was seen regardless of the type of NSAID or with short-term (0-14 days) treatment [HR 1.45 (1.24-1.69)]. When the risk of death in patients exposed [crude rate 23.3 (19.7-27.5)] vs. not exposed [crude rate 17.4 (95% CI 16.8-18.1)] to NSAIDs at the time of AF was compared, NSAID use was associated with a poorer prognosis [HR 1.35 (1.14-1.60)].
CONCLUSION: Our study suggests that the use of NSAIDs might be associated with the increased risk of AF in post-MI patients. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author 2015. For permissions please email: journals.permissions@oup.com.

Entities:  

Keywords:  Atrial fibrillation; Epidemiology; Myocardial infarction; Nationwide; Non-steroidal anti-inflammatory drugs (NSAIDs); Prognosis

Mesh:

Substances:

Year:  2015        PMID: 27533979     DOI: 10.1093/ehjcvp/pvv004

Source DB:  PubMed          Journal:  Eur Heart J Cardiovasc Pharmacother


  4 in total

Review 1.  European Heart Rhythm Association (EHRA)/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society (APHRS).

Authors:  Bulent Gorenek; Antonio Pelliccia; Emelia J Benjamin; Giuseppe Boriani; Harry J Crijns; Richard I Fogel; Isabelle C Van Gelder; Martin Halle; Gulmira Kudaiberdieva; Deirdre A Lane; Torben Bjerregaard Larsen; Gregory Y H Lip; Maja-Lisa Løchen; Francisco Marin; Josef Niebauer; Prashanthan Sanders; Lale Tokgozoglu; Marc A Vos; David R Van Wagoner; Laurent Fauchier; Irina Savelieva; Andreas Goette; Stefan Agewall; Chern-En Chiang; Márcio Figueiredo; Martin Stiles; Timm Dickfeld; Kristen Patton; Massimo Piepoli; Ugo Corra; Pedro Manuel Marques-Vidal; Pompilio Faggiano; Jean-Paul Schmid; Ana Abreu
Journal:  Eur J Prev Cardiol       Date:  2016-11-04       Impact factor: 7.804

Review 2.  European Heart Rhythm Association (EHRA)/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society (APHRS).

Authors:  Bulent Gorenek; Antonio Pelliccia; Emelia J Benjamin; Giuseppe Boriani; Harry J Crijns; Richard I Fogel; Isabelle C Van Gelder; Martin Halle; Gulmira Kudaiberdieva; Deirdre A Lane; Torben Bjerregaard Larsen; Gregory Y H Lip; Maja-Lisa Løchen; Francisco Marín; Josef Niebauer; Prashanthan Sanders; Lale Tokgozoglu; Marc A Vos; David R Van Wagoner; Laurent Fauchier; Irina Savelieva; Andreas Goette; Stefan Agewall; Chern-En Chiang; Márcio Figueiredo; Martin Stiles; Timm Dickfeld; Kristen Patton; Massimo Piepoli; Ugo Corra; Pedro Manuel Marques-Vidal; Pompilio Faggiano; Jean-Paul Schmid; Ana Abreu
Journal:  Europace       Date:  2017-02-01       Impact factor: 5.214

Review 3.  Coronary Risks Associated with Diclofenac and Other NSAIDs: An Update.

Authors:  Nicholas Moore
Journal:  Drug Saf       Date:  2020-04       Impact factor: 5.606

Review 4.  Anti-inflammatory drugs in the prevention of post-operative atrial fibrillation: a literature review.

Authors:  Homa Nomani; Amir Hooshang Mohammadpour; Seyed Mohammad Hassan Moallem; Amirhossein Sahebkar
Journal:  Inflammopharmacology       Date:  2019-10-31       Impact factor: 4.473

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.